Reata Pharmaceuticals, Inc. - (RETA): Price and Financial Metrics


Reata Pharmaceuticals, Inc. - (RETA): $37.50

1.47 (+4.08%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RETA POWR Grades

  • RETA scores best on the Growth dimension, with a Growth rank ahead of 42.04% of US stocks.
  • The strongest trend for RETA is in Momentum, which has been heading up over the past 178 days.
  • RETA's current lowest rank is in the Stability metric (where it is better than 2.75% of US stocks).

RETA Stock Summary

  • RETA's price/sales ratio is 427.18; that's higher than the P/S ratio of 99.08% of US stocks.
  • RETA's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 84.73% of US stocks.
  • Revenue growth over the past 12 months for REATA PHARMACEUTICALS INC comes in at -77.09%, a number that bests only 2.05% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to REATA PHARMACEUTICALS INC, a group of peers worth examining would be BCYC, PACB, TUYA, IMAB, and EFTR.
  • RETA's SEC filings can be seen here. And to visit REATA PHARMACEUTICALS INC's official web site, go to www.reatapharma.com.

RETA Valuation Summary

  • In comparison to the median Healthcare stock, RETA's price/sales ratio is 20865% higher, now standing at 419.3.
  • Over the past 79 months, RETA's price/sales ratio has gone up 414.1.

Below are key valuation metrics over time for RETA.

Stock Date P/S P/B P/E EV/EBIT
RETA 2022-11-25 419.3 292.4 -4.2 -5.3
RETA 2022-11-23 427.2 297.9 -4.3 -5.4
RETA 2022-11-22 414.8 289.3 -4.2 -5.2
RETA 2022-11-21 423.3 295.2 -4.3 -5.3
RETA 2022-11-18 441.5 307.9 -4.5 -5.6
RETA 2022-11-17 411.9 287.2 -4.2 -5.2

RETA Growth Metrics

    Its 5 year cash and equivalents growth rate is now at 637.02%.
  • Its 5 year net cashflow from operations growth rate is now at -1268.67%.
  • Its 3 year net cashflow from operations growth rate is now at -181.23%.
Over the past 15 months, RETA's revenue has gone down $4,609,000.

The table below shows RETA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 3.149 -276.773 -311.784
2022-06-30 10 -272.397 -304.628
2022-03-31 11.459 -248.875 -303.773
2021-12-31 11.49 -235.701 -297.386
2021-09-30 13.748 -157.909 -277.777
2021-06-30 7.758 -155.844 -271.387

RETA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RETA has a Quality Grade of C, ranking ahead of 31.15% of graded US stocks.
  • RETA's asset turnover comes in at 0.01 -- ranking 391st of 682 Pharmaceutical Products stocks.
  • INVA, SUPN, and LUMO are the stocks whose asset turnover ratios are most correlated with RETA.

The table below shows RETA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.010 1 3.336
2021-03-31 0.012 1 4.920
2020-12-31 0.013 1 8.823
2020-09-30 0.013 1 34.641
2020-06-30 0.027 1 271.349
2020-03-31 0.042 1 -40.289

RETA Price Target

For more insight on analysts targets of RETA, see our RETA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $226.44 Average Broker Recommendation 1.17 (Strong Buy)

RETA Stock Price Chart Interactive Chart >

Price chart for RETA

RETA Price/Volume Stats

Current price $37.50 52-week high $95.34
Prev. close $36.03 52-week low $18.47
Day low $36.94 Volume 211,559
Day high $39.80 Avg. volume 701,455
50-day MA $31.31 Dividend yield N/A
200-day MA $30.07 Market Cap 1.37B

Reata Pharmaceuticals, Inc. - (RETA) Company Bio


Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various serious or life-threatening diseases. The company was founded in 2002 and is based in Irving, Texas.


RETA Latest News Stream


Event/Time News Detail
Loading, please wait...

RETA Latest Social Stream


Loading social stream, please wait...

View Full RETA Social Stream

Latest RETA News From Around the Web

Below are the latest news stories about REATA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RETA as an investment opportunity.

Reata Pharmaceuticals, Inc.'s stock is down 14%, but insiders still have about US$163k in profit after buying earlier this year

Insiders who purchased Reata Pharmaceuticals, Inc. ( NASDAQ:RETA ) shares in the past 12 months are unlikely to be...

Yahoo | November 22, 2022

Can Reata Pharmaceuticals Inc. (NASDAQ: RETA) Still Be Considered A Loss When It’s Up 43.88% YTD?

During the last session, Reata Pharmaceuticals Inc. (NASDAQ:RETA)’s traded shares were 0.85 million, with the beta value of the company hitting 1.19. At the end of the trading day, the stock’s price was $37.94, reflecting an intraday gain of 7.18% or $2.54. The 52-week high for the RETA share is $95.34, that puts it down … Can Reata Pharmaceuticals Inc. (NASDAQ: RETA) Still Be Considered A Loss When It’s Up 43.88% YTD? Read More »

Marketing Sentinel | November 19, 2022

After The Stock Rose 27.77% Over The Week, Is Reata Pharmaceuticals Inc. (NASDAQ: RETA) Still A Buy?

Reata Pharmaceuticals Inc. (NASDAQ:RETA)’s traded shares stood at 1.28 million during the last session, with the company’s beta value hitting 1.15. At the close of trading, the stock’s price was $42.05, to imply an increase of 11.45% or $4.32 in intraday trading. The RETA share’s 52-week high remains $106.09, putting it -152.29% down since that … After The Stock Rose 27.77% Over The Week, Is Reata Pharmaceuticals Inc. (NASDAQ: RETA) Still A Buy? Read More »

Marketing Sentinel | November 12, 2022

Reata Pharmaceuticals Announces Participation in the Guggenheim 2022 Immunology and Neurology Conference and the Stifel 2022 Healthcare Conference

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will participate in the Guggenheim 2022 Immunology & Neurology Conference on November 14 – 15, 2022 in New York, NY, and will participate in the Stifel 2022 Healthcare Conference on November 15 – 16, 2022 in New York, NY. About Reata Reata is a clinical-stage biopharmaceutical company that develops novel ther

Business Wire | November 10, 2022

Reata Pharmaceuticals Inc. (NASDAQ: RETA) Prices Could Soar To Much Higher Levels In Coming Months

In the last trading session, 2.01 million Reata Pharmaceuticals Inc. (NASDAQ:RETA) shares changed hands as the company’s beta touched 1.15. With the company’s per share price at $40.29 changed hands at $5.39 or 15.44% during last session, the market valuation stood at $1.41B. RETA’s last price was a discount, traded about -184.93% off its 52-week … Reata Pharmaceuticals Inc. (NASDAQ: RETA) Prices Could Soar To Much Higher Levels In Coming Months Read More »

Marketing Sentinel | November 9, 2022

Read More 'RETA' Stories Here

RETA Price Returns

1-mo 25.75%
3-mo 56.18%
6-mo 36.61%
1-year -53.93%
3-year -80.78%
5-year 45.69%
YTD 42.21%
2021 -78.67%
2020 -39.53%
2019 264.40%
2018 98.09%
2017 29.73%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7093 seconds.